Nervgen Pharma (NGEN) Short term Debt (2024 - 2025)
Nervgen Pharma's (NGEN) quarterly Short term Debt came in at $6001.3 in Q4 2025, down 91.38% year-over-year from $69604.9 in Q4 2024, and down 91.38% quarter-over-quarter from $69604.9 in Q4 2024.
Powered by 
Analysis
Nervgen Pharma (NGEN) Short term Debt (2024 - 2025) Analysis & Trends
Nervgen Pharma (NGEN) has reported Short term Debt for 2 consecutive years, with $6001.3 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Short term Debt fell 91.38% year-over-year to $6001.3 in Q4 2025; TTM through Dec 2025 was $6001.3, a 91.38% decrease from a year earlier, with the FY2025 full-year figure at $6001.3, down 91.55% from the prior year.
- Short term Debt was $6001.3 for Q4 2025 at Nervgen Pharma, down from $69604.9 in the prior quarter.
- Over five years, Short term Debt peaked at $69604.9 in Q4 2024 and troughed at $6001.3 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.54 Bn | 192.56 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.55 Bn | 176.37 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.10 Bn | 123.25 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.62 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.69 Bn | 55.51 Bn | 1.37 Bn |
| 6 | Moderna | 53.54 Bn | 48.40 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.80 Bn | 30.52 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn |
| 10 | Nervgen Pharma | 152.62 Mn | 152.62 Mn | - |